Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.92 USD | -0.96% | -6.40% | -28.23% |
May. 15 | Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call | |
May. 13 | Transcript : Cytokinetics, Incorporated - Special Call |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.23% | 6.28B | B | ||
+8.29% | 114B | B+ | ||
+10.21% | 104B | B+ | ||
-11.90% | 22.41B | B+ | ||
+0.29% | 22.28B | B | ||
-5.57% | 19.07B | A- | ||
-37.36% | 18B | A- | ||
-5.17% | 17.89B | B | ||
+7.70% | 14.28B | C+ | ||
+37.65% | 12.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- Ratings Cytokinetics, Incorporated